Podcasts about ny april

BUFFALO, NY — April 21, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 3, on March 14, 2025, titled “Effects of a natural ingredients-based intervention targeting the hallmarks of aging on epigenetic clocks, physical function, and body composition: a single-arm clinical trial.” A team of researchers, led by first authors Natalia Carreras-Gallo and Rita Dargham, and corresponding author Varun B. Dwaraka from TruDiagnostic, studied how a natural anti-aging supplement called the Cel System might influence the aging process. They found that participants who took the supplement for one year showed a reduction in biological age, along with improved muscle strength and body composition. The study highlights the potential of lifestyle and nutritional supplements to support healthy aging. “The Cel System supplement range was formulated to target pathways associated with the Hallmarks of Aging when combining Cel1, Cel2, and Cel3 formulas.” Cel System is a natural supplement made from a mix of plant compounds, vitamins, and antioxidants designed to target the biological mechanisms associated with aging. Over the course of a year, 51 adults between the ages of 54 and 84 participated in the clinical trial. The group included 26 men and 25 women. Researchers tracked changes in biological age using DNA-based tests known as epigenetic clocks, along with physical performance and body composition metrics. Participants were also encouraged to walk for 10 minutes and practice mindfulness for five minutes daily. Results showed that participants experienced improvements in grip strength, lower body mobility, and reductions in body weight, waist circumference, and body mass index. These physical gains were supported by slower biological aging, as measured by multiple epigenetic clocks. In addition, the supplement appeared to reduce stem cell turnover, a key marker of aging at the cellular level. The study also reported changes in immune cell composition, suggesting that the supplement may help regulate immune function as people age. Biomarkers associated with liver function also shifted, pointing to potential improvements in organ health. However, levels of inflammation markers did not significantly change. Analysis of methylation chemical marks on DNA revealed that the supplement influenced gene activity related to stress response, brain function, and cell communication. These molecular-level changes may help explain the broader benefits seen in physical and biological aging measures. Although this was a pilot study without a control group, the findings suggest that the Cel System supplement shows potential for reducing signs of aging and improving overall health. The authors suggest future randomized controlled trials with larger sample sizes to confirm these results and explore the supplement's long-term effects on longevity. This study adds to growing evidence that targeted natural supplements may slow biological aging and extend healthspan. By combining epigenetic analysis with real-world health data, the findings offer new insight into how nutraceuticals, like Cel System, could promote long-term health and resilience. Paper: DOI: https://doi.org/10.18632/aging.206221 Corresponding author: Varun B. Dwaraka – varun.dwaraka@trudiagnostic.com Keywords: aging, epigenetic age change, physiological age change, epigenetic biomarker proxies, hallmarks of aging, nutraceutical longevity interventions To learn more about the journal, please visit our website at www.Aging-US.com​​ and connect with us on social media at: Facebook - www.facebook.com/AgingUS/ X - twitter.com/AgingJrnl Instagram - www.instagram.com/agingjrnl/ YouTube - www.youtube.com/@AgingJournal LinkedIn - www.linkedin.com/company/aging/ Pinterest - www.pinterest.com/AgingUS/ Spotify - open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY — April 16, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 3, on March 12, 2025, titled “DNA methylation entropy is a biomarker for aging.” Researchers Jonathan Chan, Liudmilla Rubbi, and Matteo Pellegrini from the University of California, Los Angeles, led a study that discovered a new way to measure changes in DNA that can help predict a person's age. This method focuses on how random certain chemical tags on DNA become over time. The team compared this new measurement, called methylation entropy, to existing methods and found it performed just as well—or even better. These findings support the idea that changes in our epigenetic information are closely linked to aging and could offer new tools for studying age-related diseases. The study focused on DNA methylation, a process where chemical marks are added to DNA and help control which genes are turned on or off. Scientists have traditionally measured average methylation levels to estimate biological age using “epigenetic clocks.” This study, however, takes a different approach. The researchers used buccal swabs (cells from inside the cheek) from 100 individuals between ages 7 and 84 and applied targeted bisulfite sequencing techniques to measure methylation entropy across 3,000 regions of the genome. Entropy in this context reflects how disordered or varied the methylation patterns are at certain sites on the DNA. The researchers discovered that as people age, the entropy of methylation at many locations changes in a reproducible way. Sometimes it increases, reflecting more random patterns, and sometimes it decreases, showing more uniformity. These shifts are not always tied to how much methylation is happening, which suggests entropy provides new information beyond what traditional methods can offer. To test how well this new metric could predict age, the team used both statistical and machine learning models. They found that methylation entropy predicted age as accurately as traditional methods, and the best results came from combining entropy with other measurements like average methylation and a method called CHALM. These combined models were able to estimate age with an average error of just five years. "[...] methylation entropy is measuring different properties of a locus compared to mean methylation and CHALM, and that loci can become both more or less disordered with age, independently of whether the methylation is increasing or decreasing with age." This research supports the growing theory that aging is partly caused by a gradual loss of epigenetic information—the biological “instructions” that help keep our cells working properly. This insight also connects with recent studies suggesting that restoring this lost information might reverse some signs of aging. While more research is needed to study methylation entropy in other tissues, this work points to a more precise and powerful way to measure biological aging, which could influence the future of aging-related treatments and therapies. Read the full paper: DOI: https://doi.org/10.18632/aging.206220 Corresponding author: Matteo Pellegrini - matteope@gmail.com Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206220 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords: entropy, DNA methylation, aging, epigenetics, epigenetic clocks To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY - April 15, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on April 4, 2025, titled “Association between two single nucleotide polymorphisms of the Prostaglandin-Endoperoxide Synthase 1 and 2 genes and cell proliferative prostatic diseases in Lebanon." The team of researchers led by first author Brock J. Sheehan and corresponding author Ruhul H. Kuddus, from Utah Valley University, discovered that a specific genetic variation in the PTGS2 gene is associated with a higher risk of benign prostate hyperplasia (BPH), a common condition in aging men. The study, which focused on Lebanese men, suggests that the C allele of the -765 G>C polymorphism in the PTGS2 gene may increase risk to this non-cancerous but problematic prostate condition. This finding could help identify men at greater risk earlier and lead to better treatment choices. Benign prostate hyperplasia and prostate cancer are two common conditions that involve abnormal cell growth in the prostate gland. While prostate cancer is malignant and potentially life-threatening, BPH is a non-cancerous enlargement that can still significantly affect quality of life. Both conditions are widespread in older men, with BPH affecting over 70% of men above 60. Researchers have long suspected that inflammation-related genes may play a role in their development. In this study, the focus was to study PTGS1 and PTGS2, genes that help produce enzymes involved in inflammation. Using DNA samples from 168 Lebanese men, including 61 with prostate cancer, 51 with BPH, and 56 healthy controls, the researchers analyzed two common gene variants. They found no link between the PTGS1 variant and either condition. However, the PTGS2 variant showed a strong association with BPH. Men carrying the C version of this gene were more than twice as likely to have BPH compared to those without it. While a similar trend was observed in men with prostate cancer, the results were less conclusive. "The C allele of SNP-765G>C of the PTGS2 gene was significantly associated with an increased risk of BPH (OR = 2.30, p-value = 0.01)." This is the first study to report a genetic link between the C allele of the -765 G>C polymorphism in the PTGS2 gene and BPH in Lebanese men. It builds on earlier findings that associated this gene variant with various cancers, including prostate, colon, and stomach cancers. Although based on a relatively small and specific population, the study offers new insight that could help improve genetic screening and guide prevention strategies. The research also points to the potential benefits of COX-2 inhibitors—drugs already used to treat prostate conditions—which may be more effective for men with certain PTGS2 gene types. Further studies in larger and more diverse groups are needed to confirm these results and explore how this gene variant influences prostate disease. In the future, simple genetic tests could help identify men at higher risk before symptoms appear, allowing for earlier and more personalized care. Continue reading: DOI: https://doi.org/10.18632/oncotarget.28710 Correspondence to: Ruhul H. Kuddus — ruhul.kuddus@uvu.edu Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY — April 14, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 3, on March 4, 2025, titled “Deciphering age-related transcriptomic changes in the mouse retinal pigment epithelium.” The study, led by first authors Sushil K. Dubey and Rashmi Dubey with corresponding author Mark E. Kleinman from East Tennessee State University, reveals that aging causes inflammation, oxidative stress, and gene disruption in the retinal pigment epithelium (RPE), a vital layer of cells in the eye. These changes may explain why older adults are more vulnerable to age-related eye diseases. The researchers also developed a human cell model to study retinal aging and test future therapies. The RPE plays a key role in maintaining retinal health. It recycles light-sensitive molecules, supports the visual cycle, and protects the retina from damage. When this layer becomes damaged, vision problems such as age-related macular degeneration can develop. In this study, researchers compared gene activity in RPE cells from young and aged mice. They found that aging increased the activity of genes involved in immune system responses, inflammation, and oxidative stress, three known triggers of tissue damage. At the same time, genes related to vision and light detection became less active, weakening the RPE's ability to support healthy vision. To reinforce these findings, the research team also aged human RPE cells in the lab. Over time, these cells showed the same patterns: inflammation increased, while genes tied to visual function decreased. This human cell model offers a practical way to explore how RPE degeneration happens over time and how it might be slowed down or reversed. The research also identified “hub genes,” which are central players of the gene networks involved in RPE aging. These are connected to immune signaling, oxidative damage, and changes in the eye's structural support. Many of these genes are already known to be involved in age-related retinal degeneration, so they may become important targets for future treatments aimed at protecting vision in older adults. “GO annotation of downregulated genes included processes related to visual perception, sensory perception of light stimulus, detection of light stimulus, detection of visible light, detection of external stimulus, detection of abiotic stimulus, phototransduction, cellular response to interferon-beta, response to interferon-beta, and response to light stimulus.” By mapping how the RPE changes with age at the molecular level, this study provides a clearer understanding of why aging leads to eye disease. It also introduces a reliable laboratory model that researchers can use to test new therapies. Altogether, the work is a key step toward developing treatments to slow or prevent vision loss tied to retinal aging. Read the full paper: DOI: https://doi.org/10.18632/aging.206219 Corresponding author: Mark E. Kleinman- kleinman@etsu.edu Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords: aging, transcriptome, retinal pigment epithelium, oxidative stress, inflammation, chronological aging To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY - April 11, 2025 – A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled “GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells." In this work, first author Diana Crisan and corresponding author Abhijit Basu from the University Hospital Ulm led a team that presents experimental evidence pointing to the protein GSK3β as a key contributor to drug resistance in melanoma. Their findings suggest that GSK3β becomes increasingly active in cancer cells during treatment, helping them survive and adapt despite ongoing therapy with BRAF inhibitors. Melanoma is a type of skin cancer in which nearly half of patients have mutations in the BRAF gene that accelerate tumor growth. While treatments targeting BRAF, known as BRAF inhibitors, initially work well, tumors often find ways to fight back. This research perspective explores how GSK3β, a protein involved in metabolism and cell survival, becomes more active in melanoma cells that develop resistance to BRAF inhibitors. Researchers treated melanoma cells with a common BRAF mutation using Dabrafenib, a widely used BRAF inhibitor. Over time, the cancer cells developed resistance and showed a marked increase in GSK3β levels. This pattern was confirmed across multiple melanoma cell models, suggesting that the finding is consistent and reliable. Importantly, the researchers observed that treating resistant cancer cells with a GSK3β inhibitor significantly reduced their growth. This result suggests that blocking this protein could restore sensitivity to treatment, highlighting GSK3β as a promising therapeutic target and supporting the idea of combining GSK3β inhibitors with existing melanoma therapies. “Remarkably, treatment of BRAFi-resistant melanoma cells with the GSK3 inhibitor LY2090314 for three weeks could overcome resistance and significantly decreased melanoma cell growth, confirming the causal role of GSK3 activation for BRAFi resistance development.” The research perspective adds to ongoing efforts to understand and overcome melanoma drug resistance. It shows that resistance is not driven only by genetic mutations but may also involve adaptive changes in the cell's internal signaling and survival mechanisms. By identifying GSK3β as a potential contributor, the authors offer a new direction for improving the durability of targeted treatments in melanoma. As research continues, GSK3β may be a critical factor in the long-term success of melanoma therapy, particularly for patients who have stopped responding to standard BRAF-targeted drugs. Continue reading: DOI: https://doi.org/10.18632/oncotarget.28711 Correspondence to: Abhijit Basu — abhijit.basu@alumni.uni-ulm.de Video short - https://www.youtube.com/watch?v=G2Tq4_r6xLw Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY — April 9, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 3, on March 5, 2025, titled “Reproductive aging, preimplantation genetic testing for aneuploidy, and the diameter of blastocysts: does size matter?” In this study, a team led by first author Jakub Wyroba from the Malopolski Institute of Fertility Diagnostics and Treatment and Andrzej Frycz Modrzewski Krakow University, and corresponding author Pawel Kordowitzki from Harvard Medical School, Nicolaus Copernicus University, and Charité, found that the size of an embryo and whether it has started hatching can help predict its genetic health. This insight could help fertility clinics select better embryos during in vitro fertilization (IVF), especially in countries or situations where advanced genetic testing is not available. As more women are choosing to have children later in life, fertility challenges related to age are becoming more common. Older maternal age is linked with a higher risk of chromosomal problems in embryos, which can reduce the success of IVF. To identify healthy embryos, many clinics use a test called preimplantation genetic testing for aneuploidy (PGT-A). However, PGT-A is expensive and not available in all countries. This study explored whether embryo quality could be predicted using physical features alone. During IVF, embryos develop in the lab for several days before being transferred into the uterus. Around day five or six, the embryo reaches a stage called the blastocyst. At this point, it begins to break out of its outer shell, called the zona pellucida. This process is called hatching, and it is an important step before the embryo can attach to the uterus and begin a pregnancy. The researchers examined 1150 embryos from women aged 26 to 45 who underwent IVF. They looked at whether the embryos were already starting to hatch and how big they were. They then compared these features with results from genetic tests. They found that smaller embryos that were already hatching were more likely to be chromosomally normal, also called “euploid.” “Of the 1150 blastocysts that underwent PGT-A analysis in this study, 49% were aneuploid.” For women over 35, 51% of small hatching embryos were euploid, compared to just 38% of larger ones that had not started to hatch. Among younger women under 35, the difference was even greater—73% of small hatching embryos were euploid, compared to 58% of large, unhatched ones. The research team also looked at what happened after the embryos were transferred. When embryos were already known to be euploid, both large and small embryos led to similar pregnancy rates. This means the size and hatching behavior mostly matter when genetic testing is not done. This study offers new guidance for IVF clinics. Choosing a small hatching embryo may improve the chances of success, especially for women of advanced age and in clinics that do not use PGT-A. This finding could help make fertility treatment more accessible and affordable. As fertility science continues to advance, insights like this provide practical tools to improve outcomes and bring new hope to individuals and families trying to conceive through IVF. DOI: https://doi.org/10.18632/aging.206215 Corresponding author: Pawel Kordowitzki- p.kordowitzki@umk.pl Video short - https://www.youtube.com/watch?v=0JJIOqWadE4 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY — April 7, 2025 — A new #research paper was #published in Aging (Aging-US) on March 18, 2025, in Volume 17, Issue 3, titled “Mitochondrial oxidative stress or decreased autophagy in osteoblast lineage cells is not sufficient to mimic the deleterious effects of aging on bone mechanoresponsiveness.” Researchers from the University of Arkansas for Medical Sciences, led by first author Ana Resende-Coelho and corresponding authors Melda Onal and Maria Almeida, investigated why bones become less responsive to exercise as people age. They studied two well-known aging-related cellular changes: oxidative stress (a buildup of harmful molecules inside cells) and reduced autophagy (a slowdown in the cell's ability to clean out and recycle damaged parts) to determine whether these could explain the decline in bone strength. Their findings revealed that these changes alone are not enough to account for the reduced bone-building response seen with aging. Physical activity is known to strengthen bones by creating mechanical stress, which activates bone cells like osteocytes to promote new bone formation. However, this process becomes less effective with age, increasing the risk of bone loss and fractures in older adults. The study aimed to uncover why this response weakens over time by focusing on specific age-related changes inside bone-forming cells. “The bone response to loading is less effective with aging, but the cellular and molecular mechanisms responsible for the impaired mechanoresponsiveness remain unclear.” The research team used a well-established mouse model in which pressure was applied to the tibia, simulating the effects of exercise. As expected, bones from older mice showed a weaker response compared to those of younger mice. However, when the researchers examined younger mice genetically modified to have either high oxidative stress or impaired autophagy, as seen in aging, their bones still responded normally to mechanical loading. The researchers also found that damage to the bone's osteocyte network, a system of cells that helps sense and respond to mechanical forces, did not prevent a healthy bone-building response in mice with autophagy deficiencies. This challenges the long-standing idea that deterioration of this cell network is a main cause of age-related bone decline. These results are significant because they eliminate two widely suspected causes of the aging skeleton's reduced responsiveness to exercise. While oxidative stress and autophagy dysfunction are common in older bone, they are not solely responsible for its reduced ability to grow stronger under physical stress. The authors suggest that future studies should explore other possible factors, such as changes in energy metabolism or how bone cells communicate. Overall, this study shows that bone aging is more complex than previously thought. Protecting bone health in older adults may require new strategies that go beyond targeting oxidative stress or autophagy. DOI - https://doi.org/10.18632/aging.206213 Corresponding authors - Melda Onal - MOnal@uams.edu, and Maria Almeida - schullermaria@uams.edu Video short - https://www.youtube.com/watch?v=fHQhA6rOaDc Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206213 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, Atg7, tibia compressive loading, Sod2, Osx1-Cre, osteocytes Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY - April 8, 2025 – A new #editorial was #published in Oncotarget, Volume 16, on April 4, 2025, titled “Deep learning-based uncertainty quantification for quality assurance in hepatobiliary imaging-based techniques." Dr. Yashbir Singh from Mayo Clinic and his colleagues discussed how artificial intelligence (AI) can improve liver imaging by recognizing when it might be wrong. This approach, called “uncertainty quantification,” helps clinicians better detect liver cancer and other diseases by pointing out areas in medical scans that need a second look. The authors explain how these AI tools could make imaging results more accurate and reliable, which is especially important when diagnosing serious conditions like liver tumors. Liver and bile duct imaging is difficult because of the organ's complex structure and differences in image quality. Even skilled radiologists can struggle to identify small or hidden tumors, especially in patients with liver damage or scarring. The editorial explains how new AI models not only read medical images but also measure their own confidence. When the AI system is unsure, it can alert clinicians to take a closer look. This extra layer of information can reduce missed diagnoses and improve early detection of liver cancer. One of the most advanced tools described in the editorial is called AHUNet (Anisotropic Hybrid Network). This AI model works with both 2D and 3D images and can highlight which parts of a scan it is most confident about. It performed well when measuring the entire liver and showed how its confidence dropped when scanning smaller or multiple lesions. This feature helps clinicians know when more testing or review is needed. The authors also looked at other AI models used in liver imaging. Some tools were able to analyze liver fat using ultrasound images and give clinicians both a result and a confidence score. Others improved the speed and accuracy of liver magnetic resonance imaging (MRI) scans, helping to create clear images in less time. These advancements could help hospitals work faster and provide better care. The editorial highlights how this technology can be especially helpful in smaller clinics. If they do not have liver specialists, they could still use AI systems that flag uncertain results and send them to larger centers for review. Such an approach could improve care in rural or less-resourced areas. “Radiology departments should develop standardized reporting templates that incorporate uncertainty metrics alongside traditional imaging findings.” By using AI tools that know when to second-guess themselves, clinicians may soon have more reliable methods for detecting liver cancer and monitoring liver disease. The authors suggest that uncertainty-aware AI may soon become a vital part of everyday medical imaging, supporting faster and more accurate decisions in liver disease care. DOI: https://doi.org/10.18632/oncotarget.28709 Correspondence to: Yashbir Singh — singh.yashbir@mayo.edu Video short - https://www.youtube.com/watch?v=Zm0QASQ_YSI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28709 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords: cancer, deep learning, uncertainty quantification, radiology, hepatobiliary imaging To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

BUFFALO, NY - April 4, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on March 27, 2025, titled “Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT." Researchers from Brown University, led by first author Lanlan Zhou and corresponding author Wafik S. El-Deiry, have shown that combining a new class of drugs called imipridones with standard glioblastoma treatments significantly improves outcomes in mice. The study tested ONC201 and its analog ONC206 in combination with radiation therapy and the chemotherapy drug temozolomide (TMZ), a regimen referred to as IRT. This triple therapy slowed tumor growth and extended survival in a mouse model of glioblastoma, offering a potential new strategy for one of the most aggressive and treatment-resistant brain cancers. Glioblastoma is a fast-growing brain tumor with a poor prognosis and limited treatment options. Standard care typically includes surgery, radiation, and TMZ, but most patients still face a short life expectancy. While ONC201 and ONC206 are currently being studied in clinical trials as single agents, there has been limited information on how they interact with standard therapies. This study is the first to show that both drugs work synergistically with radiation and TMZ, strengthening their overall effects. The results showed that in both laboratory-grown tumor cells and mice, the triple therapy significantly slowed cancer cell growth, reduced tumor size, and prolonged survival compared to using any single or double treatment. Mice treated with IRT lived an average of 123 days, with some surviving more than 200 days—far longer than the 44 to 103 days observed with other treatment combinations. In addition to directly killing tumor cells, ONC201 and ONC206 lowered the expression of MGMT, a protein that helps tumors resist chemotherapy, making the treatment more effective. The researchers also found that the triple therapy reshaped the tumor environment. It decreased levels of harmful molecules that promote tumor growth and immune evasion while increasing signals that activate the immune system. This dual action—directly attacking tumors and boosting immune responses—adds to the potential impact of this treatment approach. “Overall, our preclinical findings support further exploration of the ONC201 and ONC206 IRT regimen as a potential treatment for GBM and diffuse gliomas with H3K27M mutations.” While these findings are based on preclinical mouse models, they offer strong support for advancing this triple therapy to clinical trials. ONC201 and ONC206 are promising due to their ability to cross the blood-brain barrier and enhance the effects of standard treatment. This combination could lead to more effective therapies for glioblastoma and other hard-to-treat brain tumors. DOI - https://doi.org/10.18632/oncotarget.28707 Correspondence to - Wafik S. El-Deiry - wafik@brown.edu Video short - https://www.youtube.com/watch?v=Q_mXy8mana0 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28707 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY — April 3, 2025 — Aging (Aging-US) is pleased to announce a special Call for Papers for a commemorative collection honoring the legacy of Dr. Mikhail (Misha) Blagosklonny, the founding editor of the journal and a pioneer in aging biology. His groundbreaking work shaped fundamental concepts in the field, particularly regarding the role of mTOR in aging and cancer, the use of rapamycin, bypassing senescence during the process of transformation, personalized medicine, and theories on why we age. This special collection will explore key themes central to Dr. Blagosklonny's scientific contributions, with a focus on mechanistic insights, translational approaches, and theoretical perspectives. We invite original research, reviews, and perspective articles covering topics such as: The role of mTOR in aging and age-related diseases Rapamycin and other pharmacological strategies to extend lifespan Senescence bypass and its implications for cancer and regenerative medicine Personalized medicine approaches in aging and longevity research Theoretical models and evolutionary perspectives on aging The special issue will be guest-edited by leading scientist in the field, David Gems, who will oversee the selection of high-quality contributions that reflect the depth and impact of Dr. Blagosklonny's work. We encourage researchers working on these topics to submit their manuscripts and contribute to this tribute to one of the most influential figures in aging research. SUBMISSION DETAILS: Submission Deadline: December 1, 2025 Manuscript Format: Please follow the journal's submission guidelines Peer Review: All submissions will undergo a rigorous peer-review process Submission Link: https://aging.msubmit.net/cgi-bin/main.plex We look forward to your contributions to this special issue and to honoring Dr. Blagosklonny's enduring impact on the field of aging research. To learn more about Aging (Aging-US), please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY — April 1, 2025 — A new #research paper was #published in Aging (Aging-US) on March 29, 2025, as the #cover of Volume 17, Issue 3, titled “Differential senolytic inhibition of normal versus Aβ-associated cholinesterases: implications in aging and Alzheimer's disease.” In this study, a research team from Dalhousie University, led by Sultan Darvesh, discovered that certain anti-aging compounds, known as senolytics, can block harmful brain enzymes linked to Alzheimer's disease (AD) without affecting healthy ones. Senolytics are compounds that help clear out damaged or “zombie” cells that build up with age and contribute to inflammation and tissue dysfunction. This work provides new insight into how AD-related damage can be precisely targeted, leading the way for safer treatments that protect memory and brain health in older adults. Alzheimer's disease is one of the most common causes of memory loss and dementia. A hallmark of the disease is the buildup of sticky protein clumps in the brain, known as amyloid-beta plaques. Two enzymes—acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)—are found near these plaques. While these enzymes play important roles in brain function, they can also contribute to AD progression when they attach to plaques. Drugs that target these enzymes are already used to help with memory, but they often block both harmful and healthy forms, which can cause unwanted side effects. To investigate a better solution, researchers tested six compounds that are known for their anti-aging or brain-boosting properties. They wanted to know if these compounds could block only the harmful AChE and BChE enzymes forms linked to Alzheimer's disease. Using brain tissue samples from AD patients and enzyme activity assays, they discovered that compounds such as dasatinib and nintedanib, both senolytics, were able to block the forms of AChE and BChE associated with amyloid-beta plaques. These compounds did not affect normal brain enzymes, though. “We show that the selected senolytics and nootropic inhibit ChEs associated with plaques but not the enzymes associated with normal neural elements.” The study also used computer modeling to explore how these compounds interact with the enzymes. The models showed that the enzymes change shape when near plaques, making them easier for certain compounds to target. This change may explain how the drugs can selectively affect only the diseased areas of the brain. While not all compounds worked equally well, the findings offer a new strategy for treating AD. By focusing on the differences between healthy and diseased enzyme forms, researchers may be able to design more precise and effective therapies. This selective approach could improve memory, reduce inflammation, and avoid the side effects of AD's current treatments. In summary, this research opens new possibilities for treating Alzheimer's disease in a more targeted way. It also highlights how discoveries in aging and brain health can work together to create better therapies for neurodegenerative diseases. DOI - https://doi.org/10.18632/aging.206227 Corresponding author - Sultan Darvesh - sultan.darvesh@dal.ca Video short - https://www.youtube.com/watch?v=CJQFpG9Jn6Y Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206227 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY - April 2, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on March 21, 2025, titled “NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma." Researchers Andrea Gunnell, Scott T. Kimber, Richard Houlston, and Martin Kaiser from The Institute of Cancer Research, London, studied how a gene called NSD2 affects the behavior of multiple myeloma (MM) cells. Their findings reveal that NSD2 plays a key role in helping cancer cells retain their identity as plasma cells—white blood cells that normally help the immune system fight infections. This discovery could shape future treatment strategies for patients with a high-risk form of MM known as t(4;14) myeloma. Multiple myeloma is a type of blood cancer that begins in plasma cells found in the bone marrow. About 20% of patients have a genetic change called t(4;14), which makes the NSD2 gene highly active. The research team compared two types of myeloma cells: one with high NSD2 activity and one where NSD2 was turned off. They found that when NSD2 is active, it changes how DNA is folded and how genes are switched on or off, especially genes that help the cells act like plasma cells. When NSD2 was turned off, important markers like CD38 were reduced, and other genes normally silent in plasma cells were activated. The study indicated that NSD2 does not directly affect the main genes responsible for plasma cell creation. Instead, it influences many other genes that help maintain the cancer cell's identity, which contributes to cancer growth and survival. The researchers also observed physical changes in the cancer cells. Cells with active NSD2 looked and behaved more like typical plasma cells, while cells without NSD2 appeared more immature and lost important surface markers. These changes were linked to differences in how the DNA was organized inside the cells. These findings are especially important as new drugs are being developed to block NSD2. The study suggests that turning off NSD2 could change how MM cells respond to existing treatments. For example, if NSD2 is blocked and CD38 levels drop, the change might affect therapies that target CD38. However, the rise of other immune-related genes might make certain immunotherapies more effective. “Identifying the biological consequences of NSD2 over-expression in MM is not only relevant to informing new therapeutic interventions through indirect targeting of downstream effectors, but also to anticipate possible consequences of targeting NSD2 directly.” In summary, this study shows how NSD2 helps myeloma cells keep their cancerous identity by reorganizing the DNA and influencing gene activity. Understanding this role could help researchers design better treatment approaches and possibly overcome resistance to current therapies in t(4;14) myeloma. DOI - https://doi.org/10.18632/oncotarget.28706 Correspondence to - Andrea Gunnell - andrea.gunnell@icr.ac.uk Video short - https://www.youtube.com/watch?v=hibkjUpRq7I Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

How does Reiki fit into the world of modern healthcare? In this episode of Reiki from the Farm™, Pam Allen-LeBlanc and Tracey Sullivan share the inspiration and process behind their groundbreaking new course, Healthcare Reiki. Together, they discuss the transformative role of Reiki in healthcare settings, the importance of practitioners maintaining their own wholeness, and how this course bridges the gap between holistic and clinical care.Pam and Tracey also answer key questions about the course and its applications, offering insights into the integration of Reiki into healthcare environments.  It's not just for people who already work in healthcare.The episode concludes with a calming and empowering meditation from the course to allow you to experience this wonderful new healing energy.Register for the class in SilverBay, NY April 30-May 1 Learn more about the 2025 NorthEast Reiki Retreat May 2-4______Pam Allen-LeBlanc is a scientist, businesswoman, and Licensed Reiki Master Teacher (LRMT) with the International Center for Reiki Training.Get in Touch with Pam:pam@reikifromthefarm.comwww.reikifromthefarm.comNewsletter & invitation to Reiki Shares: http://eepurl.com/dFm-19  Tracey Sullivan is a  Licensed Reiki Master Teacher and is also certified in Holographic Sound Healing, Jikiden Reiki, Reiki Sound Therapy, and is a Medical Reiki™ Master with Raven Keyes. Get in Touch with Tracey:www.reikiintegration.comA special thanks goes out to Music from Pixabay for the intro music and to Nate Miller for the meditation music.Register for our newsletter! Instagram Facebook Youtube pam@reikifromthefarm.com

Episode 715: October 6, 2024 playlist: Liquid Liquid, "Optimo - Instrumental Mix by Optimo (Espacio)" (Bellhead / Optimo (Remix)) 2024 DFA Kim Deal, "Crystal Breath" (Nobody Loves You More) 2024 4AD Severed Heads, "Untitled 2" (Ear Bitten) 2024 Dark Entries Los Agentes Secretos, "Loco Poco A Poco" (Back Up Dos: Mexican Tecno Pop 1980-1989) 2024 Dark Entries mHz, "Brass (Loscil)" (Material Prosody) 2024 Room40 Troller, "At the Primordial Bottom of Everything" (Today) 2024 [self-released] Mark Templeton, "Closing/Scene" (Two Verses) 2024 Faitiche Onkonomiyaki Labs, "Stuttering Sundown" (Metal Massage Pleasure Centre) 2024 Onkonomiyaki Labs Deadly Headley, "Without A Love Like Yours (with Bim Sherman)" (35 Years From Alpha) 2024 On-U Sound Windy and Carl, "My Love" (Live At Community School Of Music And Arts * Ithaca, NY April 24th 2009) 2024 Blue Flea Sunroof, "Ensnare" (Ensnare) 2024 Mute claire rousay, "iii" (The Bloody Lady) 2024 Viernulvier Email podcast at brainwashed dot com to say who you are; what you like; what you want to hear; share pictures for the podcast of where you're from, your computer or MP3 player with or without the Brainwashed Podcast Playing; and win free music! We have no tracking information, no idea who's listening to these things so the more feedback that comes in, the more frequent podcasts will come. You will not be put on any spam list and your information will remain completely private and not farmed out to a third party. Thanks for your attention and thanks for listening.

For this special BONUS episode, we asked our Patrons to send in a cover of a song they feel is better than the original. As usual, they did NOT disappoint! Warning: Hot takes ahead!! Songs discussed in this episode: Hallelujah - John Cale, Jeff Buckley, Rufus Wainwright, K.D. Lang, Neil Diamond and Brandi Carlile Seven Days Too Long - Dexys Midnight Runners Black Diamond - The Replacements Swinging Party - Lorde This Guy's In Love With You - Faith No More I Am, I Said - Killdozer Don't Let Me Down - Dillard & Clark Let It Be Me - The Everly Brothers Fade Away - The New Age Steppers Satisfied Mind - Jonathan Richman Jump (Loaded version) - Aztec Camera Moonage Daydream - Zen Guerrilla The Briar and the Rose - Holly Cole Do You Wanna Dance - Ramones Ruby's Arms - Megan Mullally and Supreme Music Program Me And Bobby McGee - Janis Joplin Suzannah's Still Alive - Cardiacs Steppin' Stone - Minor Threat White Wedding - Roland S Howard Neon Lights - Love Tractor By The Time I Get To Phoenix - Nick Cave and the Bad Seeds Superstar - Bette Midler Run To Me - Laurie Lindeen Only Love Can Break Your Heart - St Etienne I Know It's Over (Live at Sony Studios in New York, NY - April, 1995) - Jeff Buckley

BUFFALO, NY- April 30, 2024 – A new #researchpaper was #published on the #cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 8, entitled, “Senescent characteristics of human corneal endothelial cells upon ultraviolet-A exposure.” In this new study, researchers Kohsaku Numa, Sandip Kumar Patel, Zhixin A. Zhang, Jordan B. Burton, Akifumi Matsumoto, Jun-Wei B. Hughes, Chie Sotozono, Birgit Schilling, Pierre-Yves Desprez, Judith Campisi (1948-2024), and Koji Kitazawa from Buck Institute for Research on Aging, Kyoto Prefectural University of Medicine, University of Cambridge, and California Pacific Medical Center investigated the senescent phenotypes of human corneal endothelial cells (hCEnCs) upon treatment with ultraviolet (UV)-A. “We assessed cell morphology, senescence-associated β-galactosidase (SA-β-gal) activity, cell proliferation and expression of senescence markers (p16 and p21) in hCEnCs exposed to UV-A radiation, and senescent hCEnCs induced by ionizing radiation (IR) were used as positive controls.” The researchers performed RNA sequencing and proteomics analyses to compare gene and protein expression profiles between UV-A- and IR-induced senescent hCEnCs — they also compared the results to non-senescent hCEnCs. Cells exposed to 5 J/cm2 of UV-A or to IR exhibited typical senescent phenotypes, including enlargement, increased SA-β-gal activity, decreased cell proliferation and elevated expression of p16 and p21. RNA-Seq analysis revealed that 83.9% of the genes significantly upregulated and 82.6% of the genes significantly downregulated in UV-A-induced senescent hCEnCs overlapped with the genes regulated in IR-induced senescent hCEnCs. Proteomics also revealed that 93.8% of the proteins significantly upregulated in UV-A-induced senescent hCEnCs overlapped with those induced by IR. In proteomics analyses, senescent hCEnCs induced by UV-A exhibited elevated expression levels of several factors part of the senescence-associated secretory phenotype. “In this study, where senescence was induced by UV-A, a more physiological stress for hCEnCs compared to IR, we determined that UV-A modulated the expression of many genes and proteins typically altered upon IR treatment, a more conventional method of senescence induction, even though UV-A also modulated specific pathways unrelated to IR.” DOI - https://doi.org/10.18632/aging.205761 Corresponding author - Koji Kitazawa - kkitazaw@koto.kpu-m.ac.jp Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205761 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts About Aging-US Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY- April 29, 2024 – Oncotarget is a contributing #sponsor at the 19th International p53 Workshop, organized by the International Center for Genetic Engineering and Biotechnology (ICGEB), which takes place from May 13–16, 2024, in Trieste, Italy. “Groundbreaking research and cutting-edge advancements in the field of the most studied human gene and most frequently mutated gene in cancer, will take center stage at the 19th International p53 Workshop.” – ICGEB.org Among the 24 invited speakers at the 19th International p53 Workshop, 18 speakers have published new research on p53 in Oncotarget. These distinguished speakers who have published with Oncotarget include Dr. Andrei Gudkov — one of Oncotarget's founding Editors-in-Chief. Dr. Gudkov will be speaking in the session on “p53 Inflammation and Immunity” and moderating the session on “Targeting p53 in Human Disease.” “The event will gather leading scientists, clinicians, and researchers from around the world providing a unique opportunity to delve into the latest discoveries and innovations related to TP53 biology and explore the intricate role of TP53 in cancer and its potential for transformative impact in oncology.” – ICGEB.org About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

BUFFALO, NY- April 24, 2024 – A new #researchpaper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 7, entitled, “Using genetics and proteomics data to identify proteins causally related to COVID-19, healthspan and lifespan: a Mendelian randomization study.” The COVID-19 pandemic poses a heavy burden on public health and accounts for substantial mortality and morbidity. Proteins are building blocks of life, but specific proteins causally related to COVID-19, healthspan and lifespan, have not been systematically examined. In this new study, researchers Jie V. Zhao, Minhao Yao, and Zhonghua Liu from The University of Hong Kong and Columbia University conducted a Mendelian randomization study to assess the effects of 1,361 plasma proteins on COVID-19, healthspan and lifespan, using large GWAS of severe COVID-19 (up to 13,769 cases and 1,072,442 controls), COVID-19 hospitalization (32,519 cases and 2,062,805 controls) and SARS-COV2 infection (122,616 cases and 2,475,240 controls), healthspan (n = 300,477) and parental lifespan (~0.8 million of European ancestry). “We included both COVID-19 and healthspan and lifespan in the outcome, because COVID-19 which occurred in recent years reflects a new threat to longevity, whilst healthspan and lifespan reflect overall morbidity and mortality.” The researchers identified 35, 43, and 63 proteins for severe COVID, COVID-19 hospitalization, and SARS-COV2 infection, and 4, 32, and 19 proteins for healthspan, father's attained age, and mother's attained age. In addition to some proteins reported previously, such as SFTPD related to severe COVID-19, the team identified novel proteins involved in inflammation and immunity (such as ICAM-2 and ICAM-5 which affect COVID-19 risk, CXCL9, HLA-DRA and LILRB4 for healthspan and lifespan), apoptosis (such as FGFR2 and ERBB4 which affect COVID-19 risk and FOXO3 which affect lifespan) and metabolism (such as PCSK9 which lowers lifespan). They found 2, 2, and 3 proteins shared between COVID-19 and healthspan/lifespan, such as CXADR and LEFTY2, shared between severe COVID-19 and healthspan/lifespan. Three proteins affecting COVID-19 and seven proteins affecting healthspan/lifespan are targeted by existing drugs. “Our study provided novel insights into protein targets affecting COVID-19, healthspan and lifespan, with implications for developing new treatment and drug repurposing.” DOI - https://doi.org/10.18632/aging.205711 Corresponding authors - Jie V. Zhao - janezhao@hku.hk, and Zhonghua Liu - zl2509@cumc.columbia.edu Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts About Aging-US Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY- April 23, 2024 – A new #researchpaper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 7, entitled, “The coupling between healthspan and lifespan in Caenorhabditis depends on complex interactions between compound intervention and genetic background.” Aging is characterized by declining health that results in decreased cellular resilience and neuromuscular function. The relationship between lifespan and health, and the influence of genetic background on that relationship, has important implications in the development of pharmacological anti-aging interventions. In this new study, researchers Stephen A. Banse, E. Grace Jackson, Christine A. Sedore, Brian Onken, David Hall, Anna Coleman-Hulbert, Phu Huynh, Theo Garrett, Erik Johnson, Girish Harinath, Delaney Inman, Suzhen Guo, Mackenzie Morshead, Jian Xue, Ron Falkowski, Esteban Chen, Christopher Herrera, Allie J. Kirsch, Viviana I. Perez, Max Guo, Gordon J. Lithgow, Monica Driscoll, and Patrick C. Phillips from the University of Oregon, The State University of New Jersey (Rutgers), The Buck Institute for Research on Aging, and National Institute on Aging assessed swimming performance as well as survival under thermal and oxidative stress across a nematode genetic diversity test panel to evaluate health effects for three compounds previously studied in the Caenorhabditis Intervention Testing Program and thought to promote longevity in different ways – NP1 (nitrophenyl piperazine-containing compound 1), propyl gallate, and resveratrol. “Overall, we find the relationships among median lifespan, oxidative stress resistance, thermotolerance, and mobility vigor to be complex.” The researchers showed that oxidative stress resistance and thermotolerance vary with compound intervention, genetic background, and age. The effects of tested compounds on swimming locomotion, in contrast, are largely species-specific. In this study, thermotolerance, but not oxidative stress or swimming ability, correlates with lifespan. Notably, some compounds exert strong impact on some health measures without an equally strong impact on lifespan. “Our results demonstrate the importance of assessing health and lifespan across genetic backgrounds in the effort to identify reproducible anti-aging interventions, with data underscoring how personalized treatments might be required to optimize health benefits.” DOI - https://doi.org/10.18632/aging.205743 Corresponding authors - Gordon J. Lithgow - glithgow@buckinstitute.org, Monica Driscoll - driscoll@dls.rutgers.edu, and Patrick C. Phillips - pphil@uoregon.edu About Aging-US Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY - April 22, 2024 – The Longevity & Aging Series is an enlightening and progressive video interview series presented by Aging, featuring esteemed researchers discussing the latest in aging research, with a focus on their studies published by Aging. In the premiere episode of the second season of the Longevity & Aging Series, Dr. Irina Conboy and Xiaoyue (Serafina) Mei from the Department of Bioengineering and QB3 at the University of California, Berkeley, discuss a priority research paper they co-authored and published in Aging's Volume 15, Issue 17, entitled, “Fail-tests of DNA methylation clocks, and development of a noise barometer for measuring epigenetic pressure of aging and disease.” DOI - https://doi.org/10.18632/aging.205046 Corresponding Author - Irina M. Conboy - iconboy@berkeley.edu Video - https://www.youtube.com/watch?v=aYhUPpEPVv4 Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205046 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, DNA methylation, epigenetics, clocks' fail-test, biological noise About Aging-US Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

Jaylen Griffin, a young boy whose story we covered in July 2023, has been found. Jaylen, age 12, vanished from Buffalo, New York in August 2020. Now, we move on from finding Jaylen, to #justiceforjaylen BURY THE VIOLENCE: https://www.btvbuffalo.org/ ************** Follow us on: Facebook: www.facebook.com/wherearetheypodcast Instagram: @thewherearetheypodcast Email me: Canwefindthem@gmail.com Join our online detective group at Patreon: ⁠www.patreon.com/wherearetheypodcast⁠ Support our mission: ⁠https://www.buymeacoffee.com/wherearethey --- Send in a voice message: https://podcasters.spotify.com/pod/show/wherearetheypodcast/message

"I need a break from witnessing" -Josh Johnson Josh and Logan are traveling which means they're seeing chaos. In classic JJS fashion, Josh's stories are about bathroom-based madness. Then, Logan goes into too much detail about a drunken debacle he and Josh saw at a taco place. It's all...a lot. Tickets are still available to see Josh and Logan in Buffalo, NY April 18th-20th. Get tickets at ⁠https://buffalo.heliumcomedy.com/events/86017⁠ Find all other tour dates and ticket links at ⁠⁠https://www.joshjohnsoncomedy.com/tour⁠⁠ and be sure to join the waitlist for sold out shows so you'll be the first to know if more shows are added! Join the JJS Patreon for bonus podcasts, videos, and replays of virtual live shows at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/joshjohnsonshow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Find Josh's albums and socials at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/joshjohnsoncomedy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Check out Logan's projects and social media at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/logannielsen⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Get in the mailbag by emailing joshjohnsonshow@gmail.com Music by Brad Kemp. Find his stuff and hire him at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.secondbedroomstudio.com/⁠

BUFFALO, NY- April 17, 2024 – A new #researchpaper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 7, entitled, “The impact of continuous and intermittent ketogenic diets on cognitive behavior, motor function, and blood lipids in TgF344-AD rats.” Studies suggest that ketogenic diets (KD) may improve memory in mouse models of aging and Alzheimer's disease (AD). In this new study, researchers Jennifer M. Rutkowsky, Zabrisky Roland, Anthony Valenzuela, An B. Nguyen, Heui Hye Park, Natalie Six, Ilknur Dursun, Kyoungmi Kim, Pamela J. Lein, and Jon J. Ramsey from the University of California Davis and Istinye University determined whether a continuous or intermittent KD (IKD) enhanced cognitive behavior in the TgF344-AD rat model of AD. “[...] it remains to be determined whether long-term consumption of a ketogenic diet can mitigate declines in cognitive or motor behavior in a rat model of AD. Therefore, the current study aimed to determine whether a KD improves cognitive or motor behavior in the TgF344-AD rat.” At 6 months-old, TgF344-AD and wild-type (WT) littermates were placed on a control (CD), KD, or IKD (morning CD and afternoon KD) provided as two meals per day for 2 or 6 months. Cognitive and motor behavior and circulating β-hydroxybutyrate (BHB), AD biomarkers and blood lipids were assessed. Animals on a KD diet had elevated circulating BHB, with IKD levels intermediate to CD and KD. TgF344-AD rats displayed impaired spatial learning memory in the Barnes maze at 8 and 12 months of age and impaired motor coordination at 12 months of age. Neither KD nor IKD improved performance compared to CD. At 12 months of age, TgF344-AD animals had elevated blood lipids. IKD reduced lipids to WT levels with KD further reducing cholesterol below WT levels. “[...] the IKD or KD did not improve motor coordination or spatial learning memory compared to the control diet. However, KD, and to a lesser extent IKD, mitigated elevations in plasma lipids in the TgF344-AD rats. Furthermore, the KD diet decreased plasma levels of total Tau in females.” DOI - https://doi.org/10.18632/aging.205741 Corresponding author - Jennifer M. Rutkowsky - jrutkowsky@ucdavis.edu Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205741 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, ketogenic diet, Alzheimer's disease, cognitive behavior, motor function, lipids About Aging-US Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY- April 16, 2024 – A new #researchpaper was #published in Oncotarget's Volume 15 on April 12, 2024, entitled, “Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface.” The B-cell receptor regulates B-cell proliferation and apoptosis. Aberrations in BCR signaling are associated with the development and progression of B-cell malignancies, such as mantle cell lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia, many of which express the IgM type of BCR on their cellular surface. Therefore, IgM is an attractive target for therapeutic antibodies against B-cell malignancies. However, soluble IgM competitively binds to anti-IgM antibodies in the serum, and these antibodies show insufficient cytotoxic activity. Thus, antibody therapy targeting IgM is hindered by the presence of soluble IgM in the blood. In this new study, researchers Takahiro Ohashi, Sayuri Terada, Shinsuke Hiramoto, Yuko Nagata, Hirokazu Suzuki, Hitoshi Miyashita, Tetsuo Sasaki, Yasukatsu Tsukada, and Keiko Fukushima from ZENOAQ (Zenyaku Kogyo Co., Ltd.) used a bispecific antibody to address this problem. “In this study, we aimed to produce IgM-dependent bispecific antibodies targeting IgM and the other B-cell antigens such as CD20, CD32b (FcγRIIB), CD79b, and human leukocyte antigen (HLA)-DR using the Cys1m technology [10, 43–45]. Additionally, the correct IgG-like bispecific antibody structures were confirmed and their efficacies in the presence of soluble IgM were analyzed.” The researchers generated bispecific antibodies bound to IgM and other B-cell antigens such as CD20 and HLA-DR using their own bispecific antibody-producing technology, Cys1m. These bispecific antibodies directly inhibited cell proliferation via cell-cycle arrest and apoptosis in vitro, although large amounts of soluble IgM were present. Additionally, a bispecific antibody bound to IgM and HLA-DR (BTA106) depleted B-cells in cynomolgus monkeys. “These data suggest that anti-IgM/B-cell surface antigen-binding specific antibodies are promising therapeutic agents for B-cell malignancies. Moreover, the bispecific antibody modality can potentially overcome problems caused by soluble antigens.” DOI - https://doi.org/10.18632/oncotarget.28578 Correspondence to - Keiko Fukushima - keiko_fukushima@mail.zenyaku.co.jp Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28578 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, bispecific antibody, Cys1m, IgM, lymphoma, cynomolgus monkey About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

BUFFALO, NY- April 15, 2024 – A new #researchpaper was #published on the #cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 7, entitled, “Evidence of a pan-tissue decline in stemness during human aging.” Despite their biological importance, the role of stem cells in human aging remains to be elucidated. In a new study, researchers Gabriel Arantes dos Santos, Gustavo Daniel Vega Magdaleno and João Pedro de Magalhães from the Universidade de Sao Paulo, University of Birmingham and the University of Liverpool applied a machine learning method to detect stemness signatures from transcriptome data of healthy human tissues. “In this work, we applied a machine learning methodology to GTEx transcriptome data and assigned stemness scores to 17,382 healthy samples from 30 human tissues aged between 20 and 79 years.” The team found that ~60% of the studied tissues exhibit a significant negative correlation between the subject's age and stemness score. The only significant exception was the uterus, where they observed an increased stemness with age. Moreover, the researchers observed that stemness is positively correlated with cell proliferation and negatively correlated with cellular senescence. Finally, they also observed a trend that hematopoietic stem cells derived from older individuals might have higher stemness scores. “In conclusion, we assigned stemness scores to human samples and show evidence of a pan-tissue loss of stemness during human aging, which adds weight to the idea that stem cell deterioration may contribute to human aging.” DOI - https://doi.org/10.18632/aging.205717 Corresponding author - João Pedro de Magalhães - jp@senescence.info Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205717 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, longevity, stem cells, transcriptomics, senescence About Aging-US Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

Josh went on the road last week and immediately created confusion at the hotel. Then, he went on a quest for specialty Twizzlers and went to a Waffle House that wouldn't let anyone inside. But first, he and Logan discuss some theater since Logan just finished directing a play. Tickets are still available to see Josh and Logan in Buffalo, NY April 18th-20th. Get tickets at https://buffalo.heliumcomedy.com/events/86017 Find all other tour dates and ticket links at ⁠https://www.joshjohnsoncomedy.com/tour⁠ and be sure to join the waitlist for sold out shows so you'll be the first to know if more shows are added! Join the JJS Patreon for bonus podcasts, videos, and replays of virtual live shows at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/joshjohnsonshow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Find Josh's albums and socials at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/joshjohnsoncomedy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Check out Logan's projects and social media at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/logannielsen⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Get in the mailbag by emailing joshjohnsonshow@gmail.com Music by Brad Kemp. Find his stuff and hire him at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.secondbedroomstudio.com/⁠

BUFFALO, NY- April 10, 2024 – A new #researchpaper was #published in Oncotarget's Volume 15 on April 8, 2024, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.” Acute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably, growth hormone-releasing hormone (GHRH) receptor antagonist MIA-602 has been shown to impede the growth of various human cancer cell lines, including AML. In this new study, researchers Simonetta I. Gaumond, Rama Abdin, Joel Costoya, Andrew V. Schally, and Joaquin J. Jimenez from the University of Miami, Florida Atlantic University and Veterans Affairs Medical Center, Miami examined the impact of MIA-602 as monotherapy and in combination with Doxorubicin on three Doxorubicin-resistant AML cell lines, KG-1A, U-937, and K-562. “Given the role of GHRH in multiple cancer types, it is possible that GHRH antagonists may offer an alternative treatment approach for AML as well as drug-resistant AML, which may circumvent the side effects associated with standard chemotherapy.” The in vitro results revealed a significant reduction in cell viability for all treated wild-type cells. Doxorubicin-resistant clones were similarly susceptible to MIA-602 as the wild-type counterpart. Their in vivo experiment of xenografted nude mice with Doxorubicin-resistant K-562 revealed a reduction in tumor volume with MIA-602 treatment compared to control. “Our study demonstrates that these three AML cell lines, and their Doxorubicin-resistant clones, are susceptible to GHRH antagonist MIA-602.” DOI - https://doi.org/10.18632/oncotarget.28579 Correspondence to - Simonetta I. Gaumond - sxg1204@miami.edu Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, leukemia, AML, resistance, growth hormone-releasing hormone, MIA-602 About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

BUFFALO, NY- April 10, 2024 – A new #researchpaper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 6, entitled, “Geraniol attenuates oxidative stress and neuroinflammation-mediated cognitive impairment in D galactose-induced mouse aging model.” D-galactose (D-gal) administration was proven to induce cognitive impairment and aging in rodents' models. Geraniol (GNL) belongs to the acyclic isoprenoid monoterpenes. GNL reduces inflammation by changing important signaling pathways and cytokines, and thus it is plausible to be used as a medicine for treating disorders linked to inflammation. In this new study, researchers Peramaiyan Rajendran, Fatma J. Al-Saeedi, Rebai Ben Ammar, Basem M. Abdallah, Enas M. Ali, Najla Khaled Al Abdulsalam, Sujatha Tejavat, Duaa Althumairy, Vishnu Priya Veeraraghavan, Sarah Abdulaziz Alamer, Gamal M. Bekhet, and Emad A. Ahmed from King Faisal University, Kuwait University, Center of Biotechnology of Borj-Cedria, Saveetha University, Alexandria University, and Assiut University examined the therapeutic effects of GNL on D-gal-induced oxidative stress and neuroinflammation-mediated memory loss in mice. “Life expectancy in the 21st century is rising, resulting in more age-related illnesses, such as memory impairment and Alzheimer's disease. In this study, GNL was studied for its protective effect on D-gal-induced aging in mice.” The study was conducted using six groups of mice (6 mice per group). The first group received normal saline, then D-gal (150 mg/wt) dissolved in normal saline solution (0.9%, w/v) was given orally for 9 weeks to the second group. In the III group, from the second week until the 10th week, mice were treated orally (without anesthesia) with D-gal (150 mg/kg body wt) and GNL weekly twice (40 mg/kg body wt) four hours later. Mice in Group IV were treated with GNL from the second week up until the end of the experiment. For comparison of young versus elderly mice, 4 month old (Group V) and 16-month-old (Group VI) control mice were used. “We evaluated the changes in antioxidant levels, PI3K/Akt levels, and Nrf2 levels. We also examined how D-gal and GNL treated pathological aging changes.” Administration of GNL induced a significant increase in spatial learning and memory with spontaneously altered behavior. Enhancing anti-oxidant and anti-inflammatory effects and activating PI3K/Akt were the mechanisms that mediated this effect. Further, GNL treatment upregulated Nrf2 and HO-1 to reduce oxidative stress and apoptosis. This was confirmed using 99mTc-HMPAO brain flow gamma bioassays. “Thus, our data suggested GNL as a promising agent for treating neuroinflammation-induced cognitive impairment.” DOI - https://doi.org/10.18632/aging.205677 Corresponding authors - Peramaiyan Rajendran - prajendran@kfu.edu.sa, and Fatma J. Al-Saeedi - fatma.alsaeedi@ku.edu.kw About Aging-US Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Please visit our website at https://www.Aging-US.com​​ and connect with us on social media. MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY- April 9, 2024 – A new #researchpaper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 6, entitled, “CMS121: a novel approach to mitigate aging-related obesity and metabolic dysfunction.” Modulated by differences in genetic and environmental factors, laboratory mice often show progressive weight gain, eventually leading to obesity and metabolic dyshomeostasis. The geroneuroprotector CMS121 has a positive effect on energy metabolism in a mouse model of type 2 diabetes. In this new study, researchers Alcir L. Dafre, Saadia Zahid, Jessica Jorge Probst, Antonio Currais, Jingting Yu, David Schubert, and Pamela Maher from Salk Institute for Biological Studies, National University of Sciences and Technology (NUST) and Federal University of Santa Catarina investigated the potential of CMS121 to counteract the metabolic changes observed during the ageing process of wild type mice. “This comprehensive analysis aimed to further understand how CMS121 influences the metabolic landscape, paving the way for potential therapeutic applications beyond its established geroneuroprotective benefits.” Control or CMS121-containing diets were supplied ad libitum for 6 months, and mice were sacrificed at the age of 7 months. Blood, adipose tissue, and liver were analyzed for glucose, lipids, and protein markers of energy metabolism. The CMS121 diet induced a 40% decrease in body weight gain and improved both glucose and lipid indexes. Lower levels of hepatic caspase 1, caspase 3, and NOX4 were observed with CMS121 indicating a lower liver inflammatory status. Adipose tissue from CMS121-treated mice showed increased levels of the transcription factors Nrf1 and TFAM, as well as markers of mitochondrial electron transport complexes, levels of GLUT4 and a higher resting metabolic rate. Metabolomic analysis revealed elevated plasma concentrations of short chain acylcarnitines and butyrate metabolites in mice treated with CMS121. “The diminished de novo lipogenesis, which is associated with increased acetyl-CoA, acylcarnitine, and butyrate metabolite levels, could contribute to safeguarding not only the peripheral system but also the aging brain. By mimicking the effects of ketogenic diets, CMS121 holds promise for metabolic diseases such as obesity and diabetes, since these diets are hard to follow over the long term.” DOI - https://doi.org/10.18632/aging.205673 Corresponding authors - Pamela Maher - pmaher@salk.edu and Alcir L. Dafre - alcir.dafre@ufsc.br Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205673 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts About Aging-US Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY- April 3, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 6, entitled, “Targeting mitochondrial dysfunction using methylene blue or mitoquinone to improve skeletal aging.” Methylene blue (MB) is a well-established antioxidant that has been shown to improve mitochondrial function in both in vitro and in vivo settings. Mitoquinone (MitoQ) is a selective antioxidant that specifically targets mitochondria and effectively reduces the accumulation of reactive oxygen species. In this new study, researchers Sher Bahadur Poudel, Dorra Frikha-Benayed, Ryan R. Ruff, Gozde Yildirim, Manisha Dixit, Ron Korstanje, Laura Robinson, Richard A. Miller, David E. Harrison, John R. Strong, Mitchell B. Schaffler, and Shoshana Yakar from New York University College of Dentistry, City College of New York, The Jackson Laboratory, University of Michigan, South Texas Veterans Health Care System, and The University of Texas Health Science Center investigated the effect of long-term administration of MB or MitoQ on skeletal morphology during the aging process. “[...] we administered MB to aged (18 months old) female C57BL/J6 mice, as well as to adult male and female mice with a genetically diverse background (UM-HET3). Additionally, we used MitoQ as an alternative approach to target mitochondrial oxidative stress during aging in adult female and male UM-HET3 mice.” Although the researchers observed some beneficial effects of MB and MitoQ in vitro, the administration of these compounds in vivo did not alter the progression of age-induced bone loss. Specifically, treating 18-month-old female mice with MB for 6 or 12 months did not have an effect on age-related bone loss. Similarly, long-term treatment with MB from 7 to 22 months or with MitoQ from 4 to 22 months of age did not affect the morphology of cortical bone at the mid-diaphysis of the femur, trabecular bone at the distal-metaphysis of the femur, or trabecular bone at the lumbar vertebra-5 in UM-HET3 mice. “Based on our findings, it appears that long-term treatment with MB or MitoQ alone, as a means to reduce skeletal oxidative stress, is insufficient to inhibit age-associated bone loss. This supports the notion that interventions solely with antioxidants may not provide adequate protection against skeletal aging.” DOI - https://doi.org/10.18632/aging.205147 Corresponding author - Shoshana Yakar - sy1007@nyu.edu Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205147 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts About Aging-US Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY- April 1, 2024 – A new #research paper was #published on the #cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 6, entitled, “Altered brain morphology and functional connectivity in postmenopausal women: automatic segmentation of whole-brain and thalamic subnuclei and resting-state fMRI.” The transition to menopause is associated with various physiological changes, including alterations in brain structure and function. However, menopause-related structural and functional changes are poorly understood. In this new study, researchers Gwang-Won Kim, Kwangsung Park, Yun-Hyeon Kim, and Gwang-Woo Jeong from Chonnam National University not only compared the brain volume changes between premenopausal and postmenopausal women, but also evaluated the functional connectivity between the targeted brain regions associated with structural atrophy in postmenopausal women. “To the best of our knowledge, no comparative neuroimaging study on alterations in the brain volume and functional connectivity, especially focusing on the thalamic subnuclei in premenopausal vs. postmenopausal women has been reported.” Each of the 21 premenopausal and postmenopausal women underwent magnetic resonance imaging (MRI). T1-weighted MRI and resting-state functional MRI data were used to compare the brain volume and seed-based functional connectivity, respectively. In statistical analysis, multivariate analysis of variance, with age and whole brain volume as covariates, was used to evaluate surface areas and subcortical volumes between the two groups. Postmenopausal women showed significantly smaller cortical surface, especially in the left medial orbitofrontal cortex (mOFC), right superior temporal cortex, and right lateral orbitofrontal cortex, compared to premenopausal women (p < 0.05, Bonferroni-corrected) as well as significantly decreased functional connectivity between the left mOFC and the right thalamus was observed (p < 0.005, Monte-Carlo corrected). Although postmenopausal women did not show volume atrophy in the right thalamus, the volume of the right pulvinar anterior, which is one of the distinguished thalamic subnuclei, was significantly decreased (p < 0.05, Bonferroni-corrected). “Postmenopausal women showed significantly lower left mOFC, right lOFC, and right STC surface areas, reduced right PuA volume, and decreased left mOFC-right thalamus functional connectivity compared to premenopausal women. If replicated in an independent sample, these findings will be helpful for understanding the effects of menopause on the altered brain volume and functional connectivity in postmenopausal women.” DOI - https://doi.org/10.18632/aging.205662 Corresponding author - Gwang-Woo Jeong - gwjeong@jnu.ac.kr About Aging-US Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Please visit our website at https://www.Aging-US.com​​. MEDIA@IMPACTJOURNALS.COM

The highly anticipated return of the legendary Rodney Mullen to Hawk Vs Wolf. Rodney, Tony, and Jason discuss the free spirit nature of skaters, why they love chaos, tour hijinks, how to skate 360s, Rodney's time as a blood sprinkler, using skate tricks as self-defense, and Rodney's beautiful positivity following surgery. Tony Hawk and Rodney Mullen: Darkslides & Secret Tapes NYC, NY APRIL 4th https://www.ticketmaster.com/event/3B00603202051584 AUSTIN, TX APRIL 7th https://www.axs.com/events/526948/tony-hawk-and-rodney-mullen-darkslides-secret-tapes-tickets?skin=acllive Try BlueChew FREE when you use our promo code HAWKWOLF at checkout--just pay $5 shipping. That's BlueChew.com, promo code HAWKWOLF to receive your first month FREE. Visit BlueChew.com for more details and important safety information. Learn more about your ad choices. Visit megaphone.fm/adchoices

The highly anticipated return of the legendary Rodney Mullen to Hawk Vs Wolf. Rodney, Tony, and Jason discuss the free spirit nature of skaters, why they love chaos, tour hijinks, how to skate 360s, Rodney's time as a blood sprinkler, using skate tricks as self-defense, and Rodney's beautiful positivity following surgery. Tony Hawk and Rodney Mullen: Darkslides & Secret Tapes NYC, NY APRIL 4th https://www.ticketmaster.com/event/3B00603202051584 AUSTIN, TX APRIL 7th https://www.axs.com/events/526948/tony-hawk-and-rodney-mullen-darkslides-secret-tapes-tickets?skin=acllive Try BlueChew FREE when you use our promo code HAWKWOLF at checkout--just pay $5 shipping. That's BlueChew.com, promo code HAWKWOLF to receive your first month FREE. Visit BlueChew.com for more details and important safety information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Le rock est mort, vive ROCKLAND ! Mardi 21h-22h sur Attitude. 98.3 / 90.7 / attitudefm.com Eddie Cochran - C'mon Everybody No Doubt - Excuse Me Mr Nirvana - Heart Shaped Box (original Steve Albini 1993 mix) Nirvana - All Apologies (original Steve Albini 1993 mix) Nirvana - Pennyroyal Tea (Scott Litt mix) Garbage - Because the Night (Patti Smith cover with Screaming Females) Garbage - Girls Talk (with Brody Dalle) Brody Dalle - Meet The Foetus, Oh The Joy (with Shirley Manson) The Presidents Of The United States Of America - Back Porch (live) Alice In Chains - Would? (live at the Majestic Theatre, Brooklyn, NY - April 1996) Mad Caddies - Drinking for 11 (live) Spell Shelter - Serpent d'eau (live at What's in the woods) Millencolin - The Ballad

This week, Shama sits down with first-degree Black Belt and school owner (Vien Jiu Jitsu), April Parks. April is an educator and mom of four. Born and raised in Syracuse, NY April has always been driven by sports and competition With a background as a Division 1 Track athlete behind her April ventured onto the mats for the first time in 2011, and never looked back.As a full time working mom, April was able to garnish 3 IBJJF World Championships at Adult (Blue Gi/Purple Gi) 2 World Championships at Black Belt in Masters, 7 Pan No Gi Titles (Adult Blue-Brown, 3rd place at Black Adult, 2 Black Belt Master Titles) and a myriad of other accolades within the IBJJF. April is a Medusa CJJ veteran and the founder of Grappling Getaways, professionally organized themed travel and training camps for women.April seeks to empower and inspire whoever she can. April has invested a tremendous amount of time in sports psychology and performance mindset.Learn more about Girls in Gis:Homepage: https://www.girls-in-gis.comEvents: https://www.girls-in-gis.com/events/Shop: http://www.girls-in-gis.com/shop/Donate: http://www.girls-in-gis.com/donate/Facebook Group: https://www.facebook.com/groups/GirlsinGisFacebook Official: https://www.facebook.com/GirlsinGisTwitter: @_girls_in_gis_Instagram: https://www.instagram.com/girlsingis/Youtube: https://www.youtube.com/c/girlsingis

Christos Rafalides vibraphone Omar Kabir horn Oscar Feldman sax Lorin Cohen bass Claes Brondal drums Broadcast on WLIW FM Southampton, NY April 16, 2023 All Rights reserved, The Jam Session, Inc. 2023 --- Support this podcast: https://podcasters.spotify.com/pod/show/the-jam-session-inc/support

John Solomon, Editor in Chief of Just the News and author of Fall Out and Gregg Jarrett, author of the upcoming book, Trial of the Century, now available for pre-sale purchase online at Amazon.com and Simonandschuster.com, are here to discuss the weaponization of the FBI with the subpoena of Christopher Wray, the decay of the bureau, the involvement in the NY case against Trump by the DOJ & FBI and the attacks on Catholics and Christian outlets, one has to truly ask what is happening in NY? See omnystudio.com/listener for privacy information.

Be happy you are married or in a relationship because these dating profiles are horrendous.  Join Jim's Patreon for 3 extra Podcasts a week for $5 a month at Patreon.com/jimflorentine.  check out jim on tour at jimflorentine.com.  April 18 Shamrock Comedy Club at the Field Fort Lauderdale, FL April 21 Royal Comedy Theater Toronto, Canada April 22 Rob's Comedy Playhouse Buffalo, NY April 28 Bonkerz Comedy Club Orlando, FL

Dumb Vanity Plates like PDINFULL, DADWHIP, PASTALUV, LFS BN GD, SKOOL GRL and more are discussed.  Also a never happened story with another guilty white woman who had a crazy innocent happen once again in a grocery store and her hero son came to the rescue. Join Jim's Patreon for 3 extra Podcasts a week for $5 a month at Patreon.com/jimflorentine.  Check out Jim on tour: April 18 Shamrock Comedy Club at the Field Fort lauderdale, FL April 21 Royal Comedy Theater Toronto, Canada April 22 Rob's Comedy Playhouse Buffalo, NY April 28 Bonkerz Comedy Club Orlando, FL. All dates at Jimflorentine.com

@roylvakano_hdn Prov to NY APRIL 2nd !!!! Spanish rapper/reggaeton artist He is the next up in New England!!! Get familiar!!!! From Drink champs to Spainsh MTV Show Roy has proven why he is a Boss who earned his respect in the industry the right way! He is the definition of a leader and a truly dedicated artist when promoting and molding his craft as a artist. Truly a genuine and humble being, Roy shares his experiences and opens up about his private life like never before!!! You don't want to miss this episode truly was a dope artist to interview and watch grow!!! Upnorth City Girlz TML Truth and Power #HDN @upnorth_city_girlzFollow Now https://m.youtube.com/channel/UCv6upNjvGb2LqDqStMlnHbA#podcast #podcasting #podcastersofinstagram #podcasts #spotify #podcastlife #podcaster #music #youtube #radio #comedy #hiphop #applepodcasts #love #podcasters #podcastshow #itunes #spotifypodcast #newpodcast #interview #entrepreneur #motivation #applepodcast #s #radioshow #dj #newepisode #covid #rap He coming to talk that TALK I LIKE !!! #HDN hdnation STAND ON IT BRO U GOT IT !!! Roy L'vakano El Vakanski https://www.youtube.com/user/RoyLvakano7IGhttps://instagram.com/roylvakano_hdn?igshid=1fhr2fqjlppc7

Ticketmaster and Adafruit Announce Groundbreaking Merger, TicketFruit, to Revolutionize the Purchase of Raspberry Pi 4s New York, NY - April 1, 2023 - Today, global ticketing and event technology platform Ticketmaster and electronics manufacturer Adafruit announced their plans to merge, with a new company, named TicketFruit, marking a pivotal moment in the technology and entertainment industries. The merger is set to create unprecedented opportunities for consumers, making it easier than ever to access the popular Raspberry Pi 4 and other innovative products. This unique partnership between the ticketing giant and the renowned electronics company will offer consumers a seamless experience, integrating cutting-edge technology into the event ticketing process. The merger will also improve the distribution and availability of the Raspberry Pi 4, a popular single-board computer widely used for educational and hobbyist purposes. "We are excited about this unprecedented merger with Adafruit," said Michael Rapino, CEO of Ticketmaster. "By combining our expertise in event technology with Adafruit's dedication to creating innovative products, we aim to redefine the consumer experience. This partnership will not only make it much easier to get a Raspberry Pi 4, but also offer new and exciting ways to use this versatile device in the entertainment industry." Limor Fried, CEO of Adafruit, echoed Rapino's enthusiasm, stating, "This collaboration with Ticketmaster opens up endless possibilities to create transformative experiences for our customers. By leveraging Ticketmaster's extensive network, we can now bring the Raspberry Pi 4 to a much wider audience and introduce unique applications for this powerful platform. We are committed to breaking boundaries and exploring new horizons in technology and entertainment." The merger is expected to be completed within the next few months, after which customers can anticipate a more streamlined process for obtaining the Raspberry Pi 4, as well as other innovative products from Adafruit. The combined company will continue to focus on providing exceptional customer experiences and creating new opportunities for technological advancement in the entertainment and electronics sectors. #adafruit #ticketmaster #ticketfruit

More meaningless quotes posted on social media that help no one. Join Jim's Patreon for 3 extra Podcasts a week fopr $5 a month at Patreon.com/jimflorentine.  Check out Jim on tour: March 30 Laugh Boston Boston, MA March 31 April 1 Governers Levittown, LI, NY April 18 Shamrock Comedy Club at the Field Fort lauderdale, FL April 21 Royal Crown Theater Toronto, Canada April 22 Rob's Comedy Playhouse Buffalo, NY April 28 Bonkerz Comedy Club Orlando, FL All dates at Jimflorentine.com  

More babies that don't get there way when out at a restaurant.  One woman got so upset about her order she actually called 911.  Everybody is Awful shirts are available now at jimflorentine.com.  Check out Jim's Patreon for 3 extra Podcasts a week at patreon.com/jimflorentine.  Check out Jim on tour: March 24,25 Uncle Vinnies Point Pleasant, NJ March 30 Laugh Boston Boston, MA March 31 April 1 Governers Levittown, Long Island, NY April 19 Shamrock Comedy Club Fort Lauderdale, FL April 22 Rob's Comedy Playhouse Buffalo, NY  

GETTIN' SALTY EXPERIENCE PODCAST Ep.125 : Our special guest is Active 30 year FDNY veteran Deputy Assistant Chief Frank Leeb. Volunteer for the East Farmingdale Fire Department - Long Island, NY (April 1983- present). He got on FDNY in 1992 and was assigned to Engine 323. In 1998 he became a charter member of Squad 270. he responded to Airtrain incident and American airlines flight 587 crash. He was promoted to Lt in 2002 and was assigned to Engine 324 and then to Capt in 2007 and was assigned to Engine 76. He was promoted to BC in 2011 and worked in Battalion 46 down the road from Squad 288. Deputy Chief, Division 1 from 10/18 - 04/20 Deputy Assistant Chief, Chief of the Fire Academy 02/20 – 12/21 His highlight of his career was doing the Getting Salty - welcome to the rock!

RVD wins the ECW TV title and all three of us were there live in attendance at the Burt Flickinger Arena in downtown Buffalo NY. Tariq talks about his strong dislike of RVD matches and why he thinks that Raven stole Mike's gimmick, this breakdown makes it difficult for Jim to keep it together. The three of us recall our thoughts of the match at that time and then reflect on how good this match actually was by today's standards. The retrospective examination of this match really ruined it for us. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/sixmantagpodcast/support

BUFFALO, NY-April 25, 2022 – A new research paper, entitled, “Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study,” was published in Oncotarget on January 31, 2022, by researchers from University of Utah, University of Minnesota Duluth, Huntsman Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, Baptist Health Medical Group, MetroHealth Medical Center, Rutgers Cancer Institute of New Jersey, University of Southern California, Saint Luke's Cancer Institute, University of Kentucky, and Bristol Myers Squibb. This multidisciplinary research team analyzed tumor mutational burden (TMB) among a large cohort of patients who had been diagnosed with stage IV non-small cell lung cancer (NSCLC). The cohort included 667 patients recruited from nine different academic and community cancer centers across the United States. “The purpose of this study is to evaluate clinical outcomes by TMB among NSCLC patients treated with immunotherapy containing regimens in the first-line setting.” (Source, 2022) While having a high TMB may sound unfavorable, a higher TMB has been associated with a higher number of neoantigens. The presence of a greater number of neoantigens may potentiate a stronger immune response. Thus, TMB may be a viable biomarker of tumor response to immuno-oncology agents. “Based on the results in this study and prior research, TMB along with other biomarkers, such as PD-L1, may help identify patients more likely to benefit from first-line immunotherapy.” (Source, 2022) Results of the study confirmed the association between a higher TMB and smoking history. However, the study did not show an association between TMB and sex, age or tumor histology. The team found that, among patients treated with first-line immunotherapy, TMB levels greater than or equal to 10 mutations per megabase were significantly associated with improved overall survival and progression-free survival. DOI: https://doi.org/10.18632/oncotarget.28178 Corresponding author: Connor Willis – Connor.Willis@pharm.utah.edu Video: https://youtu.be/Q5JI4L6Moq0 Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28178 About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter – https://twitter.com/Oncotarget Facebook – https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram – https://www.instagram.com/oncotargetjrnl/ LinkedIn – https://www.linkedin.com/company/oncotarget/ Pinterest – https://www.pinterest.com/oncotarget/ LabTube – https://www.labtube.tv/channel/MTY5OA SoundCloud – https://soundcloud.com/oncotarget For media inquiries, please contact media@impactjournals.com.

Listen as I sit down with Comedienne and sketch artist Michelle Hernandez (Galleta Marron) to find out what inspires her to produce some of the most hilarious comedy I've seen in some time. She shares about her recent retirement from a job in law enforcement and her true calling, comedy. This episode is packed with laughs, personal stories and big dreams for God. We'd love to hear your thoughts about the show. Email us at iyhinnertainment@gmail.com or hit us up on socials @iyhinnertainme.Looking to catch us live? Well now you can, our Fun Friday Comedy Tour kicks off in Baldwin, NY April 8th 2022. Check our website for more dates and show locations.Fun Friday LiveSupport the show (https://www.paypal.me/IYHInnertainmentLLC)

The MORE Act is being voted on and... more! Alex Grubard digs into current cannabis news around the country on this week's episode of Weeding Out The Stoned.UPCOMING LIVE SHOWS:http://www.weedingoutthestoned.com/buy-ticketsApril 1 - The Lab (Ambler, PA)April 2 - SModCastle (Leonardo, NJ)April 9 - Sip Studios (Jersey City, NJ)April 13 - Helium Comedy Club PDX (Portland, OR)April 15 - Jewelbox Theater (Seattle, WA)April 16 - PianoFight (San Francisco, CA)April 18 - Elysian Theater (Los Angeles, CA)April 20 - Helium Comedy Club PHL (Philadelphia, PA)April 22 - Asylum NYC (New York, NY)April 23 - Emmaus Theater (Emmaus, PA)April 27 - Helium Comedy Club BUF (Buffalo, NY)April 28 - Cinemapolis (Ithaca, NY)May 13 - ComedySportz (Richmond, VA)Follow Alex Grubard:http://www.instagram.com/alexgrubardWeeding Out The Stoned is The Game Show of Sobriety Tests. A pack of comics enter. All of them are stoned but one. Can you figure out who the sober Narc is amongst all these stoners!Follow Weeding Out The Stoned:http://www.instagram.com/weedingoutthestonedhttp://www.weedingoutthestoned.comhttp://www.twitter.com/weedingstonedhttps://www.youtube.com/channel/UCHl2ZKQzh6_IkjSqw11qyOwhttps://www.bandsintown.com/a/15073677-weeding-out-the-stonedSupport the show (http://www.patreon.com/weedingoutthestoned)

Notes & Links from Today's Show True Hemp Science | Premium CBD Products Promocode: propcode Hempcast! | Rokfin (Video) (25) Hempcast! - Propaganda Report Community (locals.com) (Audio Only)   Late Madeleine Albright Predicted Putin's 'Historic Error' in Final Op-Ed on Eve of Russia's Invasion (yahoo.com)   Pandemic relief money spent on hotel, ballpark, ski slopes | AP News   Threat looms of Russian attack on undersea cables to shut down West's internet (france24.com)   Russian cyber attacks could take down internet networks across West, spy chiefs warn (the-sun.com)   Russia and Far-Right Americans Find Common Ground With Ukraine War - The New York Times (nytimes.com)   Tennessee man used fake identity for decades, feds say | Charlotte Observer   bill of neighbors live at five pm et friday march 25 https://www.youtube.com/watch?v=iF5BEWCnBHw Meetup with Monica in LA April 16 https://www.thepropreport.com/forums/topic/meetup-w-monica-in-los-angeles-ca-april-16-details-to-come/ Meetup with Monica in NY April 8 https://www.thepropreport.com/forums/topic/meetup-w-monica-in-nanuet-ny-april-8-details-to-come/ Meetup with Monica in MA April 3 https://www.thepropreport.com/forums/topic/meetup-w-monica-in-waltham-ma-april-3-6pm-9pm/ locals livestream Friday March 25 - free! https://propreport.locals.com/post/1896040/cocktails-convo-with-monica-live-at-5pmpt-friday-march-25 larry fink says the ukraine-russia war marks the end of globalization: https://www.cnbc.com/2022/03/24/blackrocks-larry-fink-who-oversees-10-trillion-says-russia-ukraine-war-is-ending-globalization.html https://www.nommeraadio.ee/meedia/pdf/RRS/Rockefeller%20Foundation.pdf https://www.bloomberg.com/news/articles/2022-03-24/fink-says-war-to-speed-shift-to-green-energy-digital-currencies?utm_campaign=socialflow-organic&utm_source=twitter&utm_content=crypto&utm_medium=social https://twitter.com/backtolife_2022/status/1506726529799176203 zelensky script flipping https://www.occrp.org/en/the-pandora-papers/pandora-papers-reveal-offshore-holdings-of-ukrainian-president-and-his-inner-circle https://www.foxnews.com/opinion/tucker-carlson-ukraine-leaders-lying?cmpid=prn_newsstand the great reshuffle https://www.weforum.org/agenda/2022/02/great-reshuffle-jobs-market-resignation/ https://www.washingtonexaminer.com/news/white-house/biden-says-jobs-report-proves-his-policies-well-positioned-to-fight-inflation https://www.bls.gov/charts/employment-situation/civilian-labor-force-participation-rate.htm   Listen, Subscribe, Share the Show, Donate. Help us keep this train rollin! The Propaganda Report on Rokfin The CFR Plots To Shut Up Critically Thinking Americans | Rokfin The Propaganda Report on Patreon Propaganda Report Community (locals.com) The Propaganda Report Store Support Our Sponsors! Donate… If you find value in the content we produce and want to help us keep this train rollin, drop us a donation via Paypal or become a Patreon. (links below) Every little bit helps. Thank you! And thank you to everyone who has and continues to support the show. It's your support that enables us to continue producing shows. Paypal Patreon Subscribe & Leave A 5-Star Review… Subscribe on iTunes Subscribe on Google Play Music Listen on Google Podcasts Listen on Tunein Listen on Stitcher Follow on Spotify Like and Follow us on Facebook Follow Monica on Twitter Follow Binkley on Twitter Subscribe to Binkley's Youtube Channel https://www.paypal.me/BradBinkley https://www.patreon.com/propagandareport https://twitter.com/freedomactradio https://twitter.com/MonicaPerezShow https://www.youtube.com/bradbinkley https://www.youtube.com/monicaperez Learn more about your ad choices. Visit megaphone.fm/adchoices

Alex Grubard digs into current cannabis news around the country on this week's episode of Weeding Out The Stoned. New Mexico is set to begin sales of recreational cannabis on April 1st and Kentucky could legalize medical marijuana, which no one thought possible in 2022. All this and more on Weeding Out The Stoned!UPCOMING LIVE SHOWS:http://www.weedingoutthestoned.com/buy-ticketsMarch 25 - Sesh Comedy (New York, NY)April 1 - The Lab (Ambler, PA)April 2 - SModCastle (Leonardo, NJ)April 9 - Sip Studios (Jersey City, NJ)April 13 - Helium Comedy Club PDX (Portland, OR)April 15 - Jewelbox Theater (Seattle, WA)April 16 - PianoFight (San Francisco, CA)April 18 - Elysian Theater (Los Angeles, CA)April 20 - Helium Comedy Club PHL (Philadelphia, PA)April 22 - Asylum NYC (New York, NY)April 23 - Emmaus Theater (Emmaus, PA)April 27 - Helium Comedy Club BUF (Buffalo, NY)April 28 - Cinemapolis (Ithaca, NY)Follow Alex Grubard:http://www.instagram.com/alexgrubardWeeding Out The Stoned is The Game Show of Sobriety Tests. A pack of comics enter. All of them are stoned but one. Can you figure out who the sober Narc is amongst all these stoners!Follow Weeding Out The Stoned:http://www.instagram.com/weedingoutthestonedhttp://www.weedingoutthestoned.comhttp://www.twitter.com/weedingstonedhttps://www.youtube.com/channel/UCHl2ZKQzh6_IkjSqw11qyOwhttps://www.bandsintown.com/a/15073677-weeding-out-the-stonedSupport the show (http://www.patreon.com/weedingoutthestoned)

Alex Grubard discusses the cannabis news of the day! New Jersey set to begin sales of recreational cannabis. Dispensaries and lounges submit applications all over Jersey City. Mike Tyson releases edibles shaped like Evander Holyfield's bitten ear. All this and more on Weeding Out The Stoned! UPCOMING LIVE SHOWS:http://www.weedingoutthestoned.com/buy-ticketsMarch 25 - Sesh Comedy (New York, NY)April 1 - The Lab (Ambler, PA)April 2 - SModCastle (Leonardo, NJ)April 9 - Sip Studios (Jersey City, NJ)April 13 - Helium Comedy Club PDX (Portland, OR)April 15 - Jewelbox Theater (Seattle, WA)April 16 - PianoFight (San Francisco, CA)April 18 - Elysian Theater (Los Angeles, CA)April 20 - Helium Comedy Club PHL (Philadelphia, PA)April 22 - Asylum NYC (New York, NY)April 23 - Emmaus Theater (Emmaus, PA)April 27 - Helium Comedy Club BUF (Buffalo, NY)April 28 - Cinemapolis (Ithaca, NY)Follow Alex Grubard:http://www.instagram.com/alexgrubardWeeding Out The Stoned is The Game Show of Sobriety Tests. A pack of comics enter. All of them are stoned but one. Can you figure out who the sober Narc is amongst all these stoners!Follow Weeding Out The Stoned:http://www.instagram.com/weedingoutthestonedhttp://www.weedingoutthestoned.comhttp://www.twitter.com/weedingstonedhttps://www.youtube.com/channel/UCHl2ZKQzh6_IkjSqw11qyOwhttps://www.bandsintown.com/a/15073677-weeding-out-the-stonedSupport the show (http://www.patreon.com/weedingoutthestoned)

Playing catch up this week on Weeding Out The Stoned - The Podcast after a quick vacation for host and creator Alex Grubard. Weeding Out The Stoned is going on tour this April, but why? Why now, Grubard? What does a post-pandemic 2022 look like for Weeding Out The Stoned? What even is The Game Show of Sobriety Tests. Let's play catch up on the #1 high-concept cannabis show, Weeding Out The Stoned! http://www.weedingoutthestoned.com/buy-ticketsMarch 25 - Sesh Comedy (New York, NY)April 1 - The Lab (Ambler, PA)April 2 - SModCastle (Leonardo, NJ)April 9 - Sip Studios (Jersey City, NJ)April 13 - Helium Comedy Club PDX (Portland, OR)April 15 - Jewelbox Theater (Seattle, WA)April 16 - PianoFight (San Francisco, CA)April 18 - Elysian Theater (Los Angeles, CA)April 20 - Helium Comedy Club PHL (Philadelphia, PA)April 22 - Asylum NYC (New York, NY)April 23 - Emmaus Theater (Emmaus, PA)April 27 - Helium Comedy Club BUF (Buffalo, NY)April 28 - Cinemapolis (Ithaca, NY)Follow Alex Grubard:http://www.instagram.com/alexgrubardWeeding Out The Stoned is The Game Show of Sobriety Tests. A pack of comics enter. All of them are stoned but one. Can you figure out who the sober Narc is amongst all these stoners!Follow Weeding Out The Stoned:http://www.instagram.com/weedingoutthestonedhttp://www.weedingoutthestoned.comhttp://www.twitter.com/weedingstonedhttps://www.youtube.com/channel/UCHl2ZKQzh6_IkjSqw11qyOwhttps://www.bandsintown.com/a/15073677-weeding-out-the-stonedSupport the show (http://www.patreon.com/weedingoutthestoned)

Here's an update on how to get tickets for the upcoming tour dates for Weeding Out The Stoned in March and April and a little about each venue.http://www.weedingoutthestoned.com/buy-ticketsMarch 3 - The Lab (Ambler, PA)March 25 - Sesh Comedy (New York, NY)April 2 - SModCastle (Leonardo, NJ)April 9 - Sip Studios (Jersey City, NJ)April 13 - Helium Comedy Club PDX (Portland, OR)April 15 - Jewelbox Theater (Seattle, WA)April 16 - PianoFight (San Francisco, CA)April 18 - Elysian Theater (Los Angeles, CA)April 20 - Helium Comedy Club PHL (Philadelphia, PA)April 22 - Asylum NYC (New York, NY)April 23 - Emmaus Theater (Emmaus, PA)April 27 - Helium Comedy Club BUF (Buffalo, NY)April 28 - Cinemapolis (Ithaca, NY)Follow Alex Grubard:http://www.instagram.com/alexgrubardWeeding Out The Stoned is The Game Show of Sobriety Tests. A pack of comics enter. All of them are stoned but one. Can you figure out who the sober Narc is amongst all these stoners!Follow Weeding Out The Stoned:http://www.instagram.com/weedingoutthestonedhttp://www.weedingoutthestoned.comhttp://www.twitter.com/weedingstonedhttps://www.youtube.com/channel/UCHl2ZKQzh6_IkjSqw11qyOwhttps://www.bandsintown.com/a/15073677-weeding-out-the-stonedSupport the show (http://www.patreon.com/weedingoutthestoned)

The Reiki Business Book Launch - chapter 3 with Tracey Sullivan, LRMTThis series of podcasts will bring us through "The Reiki Business Book" chapter by chapter.  The book I was inspired to write to help people share the gift of Reiki is almost ready!  There are so many things that stop us from sharing Reiki with others.  Tracey and Pam discuss them and chapter 3 of "The Reiki Business Book” then lead you in a healing meditation to release your obstacles and blocks with Reiki.Pam's InformationList of ICRT Classes: https://www.reiki.org/users/pamela-allen-leblanc#classesWebsite: https://www.reikifromthefarm.com/Register for our newsletter: http://eepurl.com/dFm-19Book a Reiki session:   https://squareup.com/appointments/book/7dvtqlfp939e8g/LPSC51C92BN20/servicesInstagram:  https://www.instagram.com/reikifromthefarm/Facebook:  https://www.facebook.com/hiddenbrookfarmReikiHorsesOilsYoutube channel: https://www.youtube.com/channel/UCW5ScR7ObSiPIpgnDkWkiQAemail: pam@reikifromthefarm.comTracey's InformationReiki Integration Website: www.reikiintegration.comEmail: tracey@reikiintegration.comNortheast Reiki Retreat, Silver Bay, NY April 29-May 1https://rippleeffectspiritualtherapies.org/what-we-do/nerrthank you to Music from Pixabay for the intro musicPam Allen-LeBlanc is a scientist, a businesswoman, and a Licensed Reiki Master Teacher with the International Center for Reiki Training.  She is an internationally renowned speaker and one of the co-authors of the ICRT Animal Reiki training manuals and courses.  Pam teaches Reiki, Animal Reiki, and Animal Communication online and in-person in Canada, the US, Australia, and the United Kingdom.

If you want to know what it's like to be an entrepreneur in a face-to-face business during a pandemic where you are under quarantine, this interview is important for you.If you want to know how to start a business, in the face of great uncertainty, this interview is critical for you.If you want to discover the secrets of dressing for success, this interview is a requirement for you.If you want to have a good time listening to two friends talk about working with their wives and having fun while they deliver value, you'll love this interview. In his “Inside B.S.” Interview Series Dave Lorenzo Interviews people who educate, entertain and fascinate his audience.  Today Dave interviews Chris Cartisano, the Owner of Christopher Allen Custom Clothing. During this interview Dave and Chris discuss entrepreneurship, working in a high-touch profession during a time when nobody wants to meet with you in person, and of course, HOW TO DRESS FOR SUCCESS AND PROFIT.Contact Chris Cartisano:Phone: 631-549-1105Cell: 631-335-1210 ChrisPhone: 631-335-1211 TheresaEmail:  chris@chriscartisano.comhttp://christopherallenclothiers.comHere's your guide to this wide-ranging interview:5:55 – The current coronavirus situation on Long Island, NY April 15, 20207:10 – When will people go back to work in an office?13:21 – How will business change as a result of coronavirus?16:08 – How Chris developed his value proposition for his business (and why Dave loves it).18:33 – Chris' relationship-based sales philosophy.24:23 – You're not Steve Jobs. You need to wear good clothes. Here's why.30:40 – Why Dave likes to wear suits when he meets new people.32:15 – Your clothes can are a competitive advantage. Chris explains why.34:56 – How do you select a sport coat or suit jacket to make sure it fits?37:17 – How should your pants fit? The answer will surprise you.38:25 – Belt or suspenders? Yeah, Dave really asked that question.40:53 – What's in (style-wise)? It doesn't matter as long as you are comfortable.42:00 – How do you measure someone to make sure pants fit? It depends…44:32 – How to select a type of shirt collar (there are dozens of different types).50:10 – All about accessories: Pocket Squares, Cufflinks, Ties57:15 – How Chris became a haberdasher.100:49 – Why Chris became an entrepreneur and how he started his business.1:04:24 – Chris talks about how he works with his wife and why their partnership works well.1:07:22 – How Chris sells to his natural network (like at school functions and at family events).1:16:24 – Personal Branding: Are you Adam Sandler or Jerry Seinfeld?1:20:32 – How to connect with Chris Cartisano

Host Paul Booth reviews CHASING TRANE (narrated by Denzel Washington) had its world premiere at the 2016 Telluride Film Festival and its international premiere at the 2016 Toronto International Film Festival. It was also an official selection of DOC NYC 2016 and IFDA and will be released theatrically in NY April 14th and in LA April 21st.

In this episode, we speak with Lech Wierzynski of The California Honeydrops, which is an Oakland based band who are the amalgamation of soul, blues, funk...all of the good stuff. The band is currently on tour with the legendary Bonnie Raitt. They'll be performing here in D.C. on March 26 at the Kennedy Center. Below are the rest of their tour dates. They also have a new album out called, "A River's Invitation." March 26 /// The Kennedy Center /// Washington, DC* March 29 /// Orpheum Theatre /// Boston, MA* April 1–2 /// Beacon Theatre /// New York, NY* April 17 /// Keller Auditorium /// Portland, OR* April 20 /// Paramount Theatre /// Seattle, WA* April 22 /// Grand Sierra Resort & Casino: Grand Theatre /// Reno, NV* April 23 /// Fox Theater /// Oakland, CA* April 26 /// Winspear Opera House /// Dallas, TX* April 27 /// ACL Live at The Moody Theater /// Austin, TX* April 29 /// Bayou Theater (Revention Music Center) /// Houston, TX* May 3–4 /// Ryman Auditorium /// Nashville, TN* "Lead Me Home" by The California Honeydrops "Reconsider Baby" by Lowell Fulson "So Very Hard to Go" by Tower of Power "Seventh Son" by Sly and The Family Stone "I Can't Make You Love Me" by Bonnie Raitt

"Abortion was the only choice for me."  Susan shares her two abortion experiences in the 1970s. (Published on April 21, 2015 | Listener: Melissa Madera | Location: New York, NY) Are you a fan of the podcast?  Help us continue our work and share our stories by: https://www.fracturedatlas.org/site/fiscal/profile?id=10900

Today on The Jeff Foxx Radio Show online. In honor of Women's History Month. We celebrate women making history today! Monique Lisa playwright, actress and television host is back to talk about. Her award-winning stage play "All my Struggles" At The Oberia D Dempsey Theatre 127 W 127th NY, NY April 7th 3pm and 6pm shows. Get Tickets at Moniquelisa.com We'll  also go inside the Jeff Foxx classic vault and hear a rare live studio recording of the singing group Envogue!!! All this today on The Jeff Foxx radio show online